{"id":7135,"date":"2025-01-29T14:27:32","date_gmt":"2025-01-29T13:27:32","guid":{"rendered":"https:\/\/www.medincell.com\/?p=7135"},"modified":"2026-03-16T16:55:04","modified_gmt":"2026-03-16T15:55:04","slug":"les-ventes-de-uzedy-atteignent-117-m-en-2024-premiere-annee-complete-de-commercialisation","status":"publish","type":"post","link":"https:\/\/www.medincell.com\/fr\/les-ventes-de-uzedy-atteignent-117-m-en-2024-premiere-annee-complete-de-commercialisation\/","title":{"rendered":"Les ventes de UZEDY\u00ae atteignent 117 M$ en 2024, premi\u00e8re ann\u00e9e compl\u00e8te de commercialisation"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_cta btn_style=\u00a0\u00bbmaterial\u00a0\u00bb heading_tag=\u00a0\u00bbspan\u00a0\u00bb link_type=\u00a0\u00bbnew_tab\u00a0\u00bb text_color=\u00a0\u00bb#009FE3&Prime; text_color_hover=\u00a0\u00bb#2AC4EA\u00a0\u00bb alignment=\u00a0\u00bbleft\u00a0\u00bb alignment_tablet=\u00a0\u00bbdefault\u00a0\u00bb alignment_phone=\u00a0\u00bbdefault\u00a0\u00bb display=\u00a0\u00bbblock\u00a0\u00bb display_tablet=\u00a0\u00bbinherit\u00a0\u00bb display_phone=\u00a0\u00bbinherit\u00a0\u00bb link_text=\u00a0\u00bbDownload Press Release\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.medincell.com\/wp-content\/uploads\/2025\/01\/CP_TevaFYR_29012025_FR_vf-1.pdf\u00a0\u00bb][vc_text_separator title=\u00a0\u00bb\u00a0\u00bb title_align=\u00a0\u00bbseparator_align_left\u00a0\u00bb align=\u00a0\u00bbalign_left\u00a0\u00bb style=\u00a0\u00bbdotted\u00a0\u00bb border_width=\u00a0\u00bb2&Prime; css=\u00a0\u00bb.vc_custom_1771495321861{padding-bottom: 20px !important;}\u00a0\u00bb el_class=\u00a0\u00bb<\/p>\n<h6><\/h6>\n<p>\u00ab\u00a0][vc_column_text css=\u00a0\u00bb\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]\n<p class=\"p2\"><strong>Le partenaire de Medincell, Teva Pharmaceuticals a annonc\u00e9 aujourd\u2019hui les informations suivantes :<\/strong><\/p>\n<p><strong>A propos de UZEDY\u00ae<\/strong><\/p>\n<ul>\n<li>Ventes 2024 : 117 millions de dollars dont 43 millions de dollars au quatri\u00e8me trimestre\n<ul>\n<li>+ 17% par rapport \u00e0 la pr\u00e9vision mise \u00e0 jour par Teva en novembre 2024 : 100 millions de dollars<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse; width: 100%; max-width: 500px; text-align: center;\">\n<thead>\n<tr>\n<th style=\"border: 1px solid #000; padding: 8px;\">Q1<\/th>\n<th style=\"border: 1px solid #000; padding: 8px;\">Q2<\/th>\n<th style=\"border: 1px solid #000; padding: 8px;\">Q3<\/th>\n<th style=\"border: 1px solid #000; padding: 8px;\">Q4<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border: 1px solid #000; padding: 8px;\" colspan=\"2\">40 M$<\/td>\n<td style=\"border: 1px solid #000; padding: 8px;\">35 M$<\/td>\n<td style=\"border: 1px solid #000; padding: 8px;\">43 M$<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li>Pr\u00e9vision initiale de Teva pour 2025 : 160 millions de dollars\n<ul>\n<li>vs. Pr\u00e9vision initiale de Teva pour 2024 : 80 millions de dollars<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Medincell per\u00e7oit le versement de royalties \u00ab mid- to high-single digit \u00bb sur les ventes nettes et est \u00e9ligible \u00e0 105 millions de dollars de milestones commerciaux.<\/p>\n<p><strong>A propos de l\u2019Olanzapine LAI (TEV-749 \/ mdc-TJK)<\/strong><\/p>\n<ul>\n<li>Pr\u00e9paration de la demande de mise sur march\u00e9 et du lancement :\n<ul>\n<li>Derni\u00e8re visite du dernier patient de l\u2019essai de Phase 3 attendue sous peu<\/li>\n<li>Publication des donn\u00e9es de s\u00e9curit\u00e9 \u00e0 long-terme pr\u00e9vue au deuxi\u00e8me trimestre 2025<\/li>\n<li>Soumission d\u2019une NDA* pr\u00e9vue au second semestre 2025<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&gt; <a href=\"https:\/\/ir.tevapharm.com\/news-and-events\/press-releases\/press-release-details\/2025\/Teva-Delivers-Second-Consecutive-Year-of-Growth-Announces-Strong-Financial-Results-in-Fourth-Quarter-and-Full-Year-2024-Led-by-Generics-Performance-and-Innovative-Portfolio-Growth\/default.aspx\">Communiqu\u00e9 de presse des r\u00e9sultats annuels 2024 de Teva<\/a><\/p>\n<p>&gt; <a href=\"https:\/\/events.q4inc.com\/attendee\/899170090\">Webcast et replay<\/a> de la conf\u00e9rence de pr\u00e9sentation des r\u00e9sultats annuels 2024 de Teva, aujourd&rsquo;hui \u00e0 14h00 CET<\/p>\n<p><em>*NDA (New Drug Application) : Demande officielle d&rsquo;autorisation de mise sur le march\u00e9 d&rsquo;un nouveau produit pharmaceutique, comprenant des donn\u00e9es d\u00e9taill\u00e9es sur sa s\u00e9curit\u00e9, son efficacit\u00e9, sa fabrication et son \u00e9tiquetage.<\/em>[\/vc_column_text][vc_text_separator title=\u00a0\u00bb\u00a0\u00bb title_align=\u00a0\u00bbseparator_align_left\u00a0\u00bb align=\u00a0\u00bbalign_left\u00a0\u00bb style=\u00a0\u00bbdotted\u00a0\u00bb border_width=\u00a0\u00bb2&Prime; css=\u00a0\u00bb.vc_custom_1771258943287{padding-top: 20px !important;padding-bottom: 20px !important;}\u00a0\u00bb el_class=\u00a0\u00bb<\/p>\n<h6><\/h6>\n<p>\u00ab\u00a0][vc_column_text css=\u00a0\u00bb\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]<strong>A propos de Medincell<\/strong>[\/vc_column_text][vc_column_text css=\u00a0\u00bb\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]\n<p class=\"p2\">Medincell est une soci\u00e9t\u00e9 de licensing biopharmaceutique en phase clinique et commerciale qui d\u00e9veloppe des m\u00e9dicaments injectables \u00e0 action prolong\u00e9e dans de nombreux domaines th\u00e9rapeutiques. Nos traitements innovants visent \u00e0 garantir le respect des prescriptions m\u00e9dicales, \u00e0 am\u00e9liorer l&rsquo;efficacit\u00e9 et l&rsquo;accessibilit\u00e9 des m\u00e9dicaments, et \u00e0 r\u00e9duire leur empreinte environnementale. Ils combinent des principes actifs avec notre technologie propri\u00e9taire BEPO\u00ae qui contr\u00f4le la lib\u00e9ration d&rsquo;un m\u00e9dicament \u00e0 un niveau th\u00e9rapeutique pendant plusieurs jours, semaines ou mois \u00e0 partir de l&rsquo;injection sous-cutan\u00e9e ou locale d&rsquo;un simple d\u00e9p\u00f4t de quelques millim\u00e8tres, enti\u00e8rement bior\u00e9sorbable. Le premier traitement bas\u00e9 sur la technologie BEPO\u00ae , destin\u00e9 au traitement de la schizophr\u00e9nie, a \u00e9t\u00e9 approuv\u00e9 par la FDA en avril 2023, et est maintenant distribu\u00e9 aux \u00c9tats-Unis par Teva sous le nom UZEDY\u00ae (la technologie BEPO est licenci\u00e9e \u00e0 Teva sous le nom de SteadyTeq\u2122). Nous collaborons avec des entreprises pharmaceutiques de premier plan et des fondations pour am\u00e9liorer la sant\u00e9 mondiale gr\u00e2ce \u00e0 de nouvelles options de traitement.<\/p>\n<p class=\"p2\"><em>UZEDY\u00ae et SteadyTeq\u2122 sont des marques d\u00e9pos\u00e9es de Teva Pharmaceuticals<\/em><\/p>\n<p><a href=\"https:\/\/www.medincell.com\/fr\/\"><strong>medincell.com<\/strong><\/a>[\/vc_column_text][vc_text_separator title=\u00a0\u00bb\u00a0\u00bb title_align=\u00a0\u00bbseparator_align_left\u00a0\u00bb align=\u00a0\u00bbalign_left\u00a0\u00bb style=\u00a0\u00bbdotted\u00a0\u00bb border_width=\u00a0\u00bb2&Prime; css=\u00a0\u00bb.vc_custom_1771258966470{padding-top: 20px !important;padding-bottom: 20px !important;}\u00a0\u00bb el_class=\u00a0\u00bb<\/p>\n<h6><\/h6>\n<p>\u00ab\u00a0][vc_column_text css=\u00a0\u00bb\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]\n<h6><strong>Contacts<\/strong><\/h6>\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/2&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]<strong>David Heuz\u00e9<\/strong><br \/>\nHead of Corporate and Financial Communications, and ESG<br \/>\n<a href=\"mailto:david.heuze@medincell.com\" target=\"_blank\" rel=\"noopener\">david.heuze@medincell.com<\/a> \/ +33 (0)6 83 25 21 86<\/p>\n<p><strong>Grace Kim<\/strong><br \/>\nChief Strategy Officer, U.S. Finance<br \/>\n<a href=\"mailto:grace.kim@medincell.com\" target=\"_blank\" rel=\"noopener\">grace.kim@medincell.com<\/a> \/ +1 (646) 991-4023[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/2&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]<strong>Nicolas M\u00e9rigeau \/ Arthur Rouill\u00e9<\/strong><br \/>\nMedia Relations<br \/>\n<a href=\"mailto:Medincell@newcap.eu\" target=\"_blank\" rel=\"noopener\">Medincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94<\/p>\n<p><strong>Louis-Victor Delouvrier \/ Alban Dufumier<\/strong><br \/>\nRelations Investisseurs France<br \/>\n<a href=\"mailto:Medincell@newcap.eu\" target=\"_blank\" rel=\"noopener\">Medincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_text_separator title=\u00a0\u00bb\u00a0\u00bb title_align=\u00a0\u00bbseparator_align_left\u00a0\u00bb align=\u00a0\u00bbalign_left\u00a0\u00bb style=\u00a0\u00bbdotted\u00a0\u00bb border_width=\u00a0\u00bb2&Prime; css=\u00a0\u00bb.vc_custom_1771258966470{padding-top: 20px !important;padding-bottom: 20px !important;}\u00a0\u00bb el_class=\u00a0\u00bb<\/p>\n<h6><\/h6>\n<p>\u00ab\u00a0][toggles style=\u00a0\u00bbdefault\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb][toggle color=\u00a0\u00bbDefault\u00a0\u00bb heading_tag=\u00a0\u00bbh5&Prime; heading_tag_functionality=\u00a0\u00bbdefault\u00a0\u00bb title=\u00a0\u00bbAvertissement relatif aux d\u00e9clarations prospectives\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]Ce communiqu\u00e9 de presse peut contenir des d\u00e9clarations prospectives, notamment concernant la progression des essais cliniques de la Soci\u00e9t\u00e9. M\u00eame si la Soci\u00e9t\u00e9 consid\u00e8re que ses pr\u00e9visions sont fond\u00e9es sur des hypoth\u00e8ses raisonnables, toutes d\u00e9clarations autres que des d\u00e9clarations de faits historiques que pourrait contenir ce communiqu\u00e9 de presse relatives \u00e0 des \u00e9v\u00e9nements futurs sont sujettes \u00e0 des changements sans pr\u00e9avis, \u00e0 des facteurs que la Soci\u00e9t\u00e9 ne ma\u00eetrise pas et aux capacit\u00e9s financi\u00e8res de la Soci\u00e9t\u00e9. Ces d\u00e9clarations peuvent inclure, sans que cette liste soit limitative, toutes d\u00e9clarations commen\u00e7ant par, suivies par ou comprenant des mots ou expressions tels que \u00ab objectif \u00bb, \u00ab croire \u00bb, \u00ab pr\u00e9voir \u00bb, \u00ab viser \u00bb, \u00ab avoir l\u2019intention de \u00bb, \u00ab pouvoir \u00bb, \u00ab anticiper \u00bb, \u00ab estimer \u00bb, \u00ab planifier \u00bb, \u00ab projeter \u00bb, \u00ab devra \u00bb, \u00ab peut avoir \u00bb, \u00ab probablement \u00bb, \u00ab devrait \u00bb, \u00ab pourrait \u00bb et d\u2019autres mots et expressions de m\u00eame sens ou employ\u00e9s \u00e0 la forme n\u00e9gative. Les d\u00e9clarations prospectives sont sujettes \u00e0 des risques intrins\u00e8ques et \u00e0 des incertitudes hors du contr\u00f4le de la Soci\u00e9t\u00e9 qui peuvent, le cas \u00e9ch\u00e9ant, entra\u00eener des diff\u00e9rences notables entre les r\u00e9sultats, performances ou r\u00e9alisations r\u00e9els de la Soci\u00e9t\u00e9 et ceux anticip\u00e9s ou exprim\u00e9s explicitement ou implicitement par lesdites d\u00e9clarations prospectives. Une liste et une description de ces risques, al\u00e9as et incertitudes figurent dans les documents d\u00e9pos\u00e9s par la soci\u00e9t\u00e9 aupr\u00e8s de l\u2019Autorit\u00e9 des March\u00e9s Financiers (AMF) au titre de ses obligations r\u00e9glementaires, y compris dans le document de base de la Soci\u00e9t\u00e9, enregistr\u00e9 aupr\u00e8s de l\u2019AMF le 4 septembre 2018 sous le num\u00e9ro I. 18-062, ainsi que dans les documents et rapports qui seront publi\u00e9s ult\u00e9rieurement par la Soci\u00e9t\u00e9. Par ailleurs, ces d\u00e9clarations prospectives ne valent qu\u2019\u00e0 la date du pr\u00e9sent communiqu\u00e9 de presse. Les lecteurs sont invit\u00e9s \u00e0 ne pas se fier ind\u00fbment \u00e0 ces d\u00e9clarations prospectives. Sauf exigence l\u00e9gale, la Soci\u00e9t\u00e9 ne reconna\u00eet aucune obligation de mettre \u00e0 jour publiquement ces d\u00e9clarations prospectives, ni d\u2019actualiser les raisons pour lesquelles les r\u00e9sultats av\u00e9r\u00e9s pourraient varier sensiblement des r\u00e9sultats anticip\u00e9s par les d\u00e9clarations prospectives, et ce y compris dans le cas o\u00f9 des informations nouvelles viendraient \u00e0 \u00eatre disponibles. La mise \u00e0 jour par la Soci\u00e9t\u00e9 d\u2019une ou plusieurs d\u00e9clarations prospectives n\u2019impliquera pas qu\u2019elle proc\u00e9dera ou non \u00e0 d\u2019autres actualisations de ces d\u00e9clarations prospectives ou d\u2019autres d\u00e9clarations prospectives. Ce communiqu\u00e9 de presse est publi\u00e9 \u00e0 des fins d\u2019information uniquement. Les informations qu\u2019il contient ne constituent ni une offre de vente, ni une sollicitation d\u2019offre d\u2019achat ou de souscription de titres de la Soci\u00e9t\u00e9 dans quelque juridiction que ce soit, en particulier en France. De la m\u00eame fa\u00e7on, ce communiqu\u00e9 ne constitue pas un conseil en investissement et ne saurait \u00eatre trait\u00e9 comme tel. Il n\u2019a aucun lien avec les objectifs d\u2019investissement, la situation financi\u00e8re ou les besoins sp\u00e9cifiques d\u2019un quelconque destinataire. Il ne saurait priver les destinataires d\u2019exercer leur propre jugement. Toutes les opinions exprim\u00e9es dans ce document sont sujettes \u00e0 modification sans pr\u00e9avis. La diffusion de ce communiqu\u00e9 de presse peut \u00eatre encadr\u00e9e par des dispositions restrictives du droit dans certaines juridictions. Les personnes qui viendraient \u00e0 prendre connaissance du pr\u00e9sent communiqu\u00e9 de presse sont tenues de se renseigner quant \u00e0 ces restrictions et de s\u2019y conformer.[\/vc_column_text][\/toggle][\/toggles][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_titles_title":"UZEDY\u00ae : Succ\u00e8s des ventes Teva en 2024","_seopress_titles_desc":"D\u00e9couvrez comment Medincell booste la sant\u00e9 avec ses traitements innovants et UZEDY\u00ae en partenariat avec Teva. Pr\u00e9vision 2025 \u00e0 160 millions de dollars.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"none","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"itsec_x_frame_options":"","footnotes":""},"categories":[37,38,42,39,29,43],"tags":[62],"class_list":["post-7135","post","type-post","status-publish","format-standard","category-home-fr","category-investors-fr","category-mdc-tjk-fr","category-news-fr","category-non-classifiee","category-uzedy-fr","tag-62"],"_links":{"self":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/posts\/7135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/comments?post=7135"}],"version-history":[{"count":6,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/posts\/7135\/revisions"}],"predecessor-version":[{"id":10493,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/posts\/7135\/revisions\/10493"}],"wp:attachment":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/media?parent=7135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/categories?post=7135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/tags?post=7135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}